Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 12, 2002

View Archived Issues

Cyclis licenses broad technology to expand ACT platform

Immunomedics' unlabeled CEA antibody inhibits tumor growth and enhances dacarbazine therapy

APT-3111 awarded E.U. orphan drug status for paroxysmal nocturnal hemoglobinuria

New modulators of adenosine receptors identified at Bayer

Japanese patent covers novel alpha2-adrenoceptor antagonists designed by Fuso scientists

Several related series of guanylate cyclase activators described by Bayer

New antitumor hydroxamates prepared and tested at Ono

Ono scientists design novel chemokine antagonists for asthma, arthritis, etc.

Tropane analogue RTI-336 as a potential therapeutic for cocaine abuse

New mu/delta opioid receptor agonist under study for the management of GI motility disorders

Beneficial effects for NCX-1000 in animal model of cholangitis

Major active component of TJ-135 determined using hepatic stellate cells

Data supporting ongoing clinical development of ACH-126443 for HBV presented at meetings

Effect of emerging precore stop codon mutation on anti-HBV activity of LY-582563/MCC-478

Antitumor activity of TRAIL-R1 MAb demonstrated in vitro and in vivo

Preclinical data reported for Ono-2506 at Neuroscience 2002

OraQuick rapid HIV-1 test approved

Inflazyme announces phase Ia and Ib results with IPL-512602

ENMD-0995 receives orphan drug designation

Aphton initiates clinical trials with G17DT for GERD in Europe

Pay now or pay later: new report sheds light on the economic impact of osteoporosis in the workplace

Inspire announces phase II results with INS-37217

Top-line results of phase III study of alvimopan in opioid bowel dysfunction

Evidence supporting the use of neurokinin receptor antagonists in depression

FDA designates Orathecin as a fast track drug

HuMax-CD4 to be tested in cancer patients

Cetirizine approved for pediatric use

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...